Blar i Department of Biomedicine på forfatter "Brandal, Petter"

Viser treff 1-3 av 3

    • Glioblastom hos voksne 

      Schipmann, Stephanie; Sivakanesan, Sarankan; Rath, Daniel Stavne; Brandal, Petter; Vik-Mo, Einar Osland; Bjørås, Magnar; Solheim, Ole Skeidsvoll; Ingebrigtsen, Tor; Sund, Fredrik; Bjerkvig, Rolf; Miletic, Hrvoje; Johannessen, Tor-Christian Aase; Sundstrøm, Terje (Journal article; Peer reviewed, 2023)
      Glioblastom er den vanligste formen for primær hjernekreft hos voksne, og sykdommen har en alvorlig prognose. Selv om det er gjort store fremskritt i molekylær karakteristikk, har det ikke vært større gjennombrudd i ...

    • Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study 

      Rahman, Mohummad Aminur; Brekke, Jorunn; Arnesen, Victoria Smith; Hannisdal, Marianne; Navarro, Andrea Gras; Waha, Andreas; Herfindal, Lars; Rygh, Cecilie Brekke; Bratland, Eirik; Brandal, Petter; Haász, Judit; Oltedal, Leif; Miletic, Hrvoje; Lundervold, Arvid; Lie, Stein Atle; Goplen, Dorota; Chekenya, Martha (Journal article; Peer reviewed, 2020)
      Background Glioblastoma (GBM) is an aggressive malignant brain tumor where median survival is approximately 15 months after best available multimodal treatment. Recurrence is inevitable, largely due to O6 methylguanine ...

    • Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions 

      Blakstad, Hanne Kristin; Brekke, Jorunn; Rahman, Mohummad Aminur; Arnesen, Victoria Smith; Miletic, Hrvoje; Brandal, Petter; Lie, Stein Atle; Enger, Martha; Goplen, Dorota (Journal article; Peer reviewed, 2023-02-02)
      Therapy of recurrent glioblastoma (GBM) is challenging due to lack of standard treatment. We investigated physicians’ treatment choice at recurrence and prognostic and predictive factors for survival in GBM patients from ...